Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes

Summary The efficacy and tolerance of azacitidine in higher‐risk myelodysplasia with hypocellular bone marrow (BM) are unknown. This post hoc AZA‐001 trial analysis assessed whether baseline BM cellularity affected the overall survival (OS) advantage demonstrated with azacitidine versus conventional...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2014-04, Vol.165 (1), p.49-56
Main Authors: Seymour, John F., Bennett, John M., List, Alan F., Mufti, Ghulam J., Gore, Steven D., Fenaux, Pierre, Santini, Valeria, Hetzer, Joel, Songer, Stephen, Skikne, Barry S., Beach, Charles L.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - therapeutic use
azacitidine
Azacitidine - therapeutic use
Biological and medical sciences
Biopsy
Bone Marrow - pathology
conventional care regimens
Drug Tolerance
Hematologic and hematopoietic diseases
Humans
hypocellular bone marrow
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Middle Aged
myelodysplastic syndromes
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - mortality
Myelodysplastic Syndromes - pathology
overall survival
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The efficacy and tolerance of azacitidine in higher‐risk myelodysplasia with hypocellular bone marrow (BM) are unknown. This post hoc AZA‐001 trial analysis assessed whether baseline BM cellularity affected the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.12723